2019
Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
Sardesai S, Kassem M, Morgan E, Palettas M, Stephens J, Williams N, Stover D, Van Deusen J, Wesolowski R, Lustberg M, Ramaswamy B. Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Journal Of Clinical Oncology 2019, 37: e12050-e12050. DOI: 10.1200/jco.2019.37.15_suppl.e12050.Peer-Reviewed Original ResearchDisease-free survivalPositive breast cancerHormone receptor expressionOverall survivalBreast cancerReceptor expressionPositive diseaseTumor gradeEarly-stage HER2-positive breast cancerOhio State University Comprehensive Cancer CenterSecond primary breast cancerSingle-institution retrospective analysisHER2-positive breast cancerAdjuvant ovarian suppressionHR-negative diseaseHR-negative patientsHR-positive diseaseTriple-positive diseaseAnti-estrogen therapyComplete pathologic responseSingle institution experienceKaplan-Meier methodPrimary breast cancerInvasive ductal cancerLow tumor grade
2017
Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer.
Stiff A, McQuinn C, Wesolowski R, Lustberg M, Reinbolt R, VanDeusen J, Sardesai S, Williams N, Noonan A, Dewani S, Ramaswamy B, Carson W. Effect of neoadjuvant chemotherapy on immune checkpoint expression in breast cancer. Journal Of Clinical Oncology 2017, 35: e12126-e12126. DOI: 10.1200/jco.2017.35.15_suppl.e12126.Peer-Reviewed Original ResearchNeo-adjuvant chemotherapyCD8 T cellsCD4 T cellsMore CD8 T cellsT cellsBreast cancerReceptor expressionCheckpoint inhibitorsCheckpoint expressionComplete pathologic response rateMore CD4 T cellsHormone receptorsPathologic response rateClinical stage IOperable breast cancerImmune checkpoint expressionReceptor expression changesBC subgroupsNeoadjuvant chemotherapyClinical responseProspective trialImmune checkpointsMedian agePD-1CTLA-4